Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Schrama, D; Reisfeld, RA; Becker, JC.
Antibody targeted drugs as cancer therapeutics.
Nat Rev Drug Discov. 2006; 5(2):147-159
Doi: 10.1038/nrd1957
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Schrama David
- Co-Autor*innen der Med Uni Graz
- Becker Jürgen Christian
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Treatment of cancer is a double-edged sword: it should be as aggressive as possible to completely destroy the tumour, but it is precisely this aggressiveness which often causes severe side effects - a reason why some promising therapeutics can not be applied systemically. In addition, therapeutics such as cytokines that physiologically function in a para- or autocrine fashion require a locally enhanced level to exert their effect appropriately. An elegant way to accumulate therapeutic agents at the tumour site is their conjugation/fusion to tumour-specific antibodies. Here, we discuss recent preclinical and clinical data for antibody-drug conjugates and fusion proteins with a special focus on drug components that exert their antitumour effects through normal biological processes.
- Find related publications in this database (using NLM MeSH Indexing)
- Animals -
- Antineoplastic Agents - immunology Antineoplastic Agents - therapeutic use
- Drug Delivery Systems -
- Humans -
- Immunotoxins - immunology Immunotoxins - therapeutic use
- Neoplasms - drug therapy Neoplasms - immunology
- Prodrugs -
- Recombinant Fusion Proteins - immunology Recombinant Fusion Proteins - therapeutic use